Sarama Saha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarama Saha has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Anindya Das
Department of Psychiatry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
5 shared publicationsJiya Singh
Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
5 shared publications- Partha Roy
Indian Institute of Technology Roorkee
4 shared publications Praveen Kumar Singh
Department of Biochemistry, AIIMS, Rishikesh, India
4 shared publicationsRavi Kant
All India Institute of Medical Sciences
4 shared publications- Sham S. Kakar
Department of Physiology, University of Louisville, Louisville, KY 40202, USA
4 shared publications
Latest Publications
- 16 November 2026
- Published by Wiley in Environmental Toxicology
Eugenol Suppresses Heavy Metal‐Induced Proliferation of Urinary Bladder Cancer Cells Through Modulation of DNA Demethylation and Activation of the Intrinsic Apoptotic Pathway
Epigenetic dysregulation is triggered by environmental toxins, including heavy metals. The aberrant DNA methylation, catalyzed by DNA methyltransferases (DNMTs) in response to environmental toxins, plays a critical role in several diseases such as urinary bladder carcinogenesis. Dysregulated DNMT activity leads to genome‐wide alterations in the methylation pattern. Consequently, hypermethylation of tumor suppressor genes (TSGs) and global hypomethylation may result in genomic instability, oncogene activation, altered chromatin remodeling, and apoptosis. Although several DNMT inhibitors, including 5‐azacytidine and decitabine, are clinically approved, their instability and limited target specificity restrict their therapeutic applications. Therefore, researching novel compounds analogous to DNMT inhibitors with higher specificity may be therapeutically useful. In this context, eugenol has been found as a potential epigenetic modulator in relation to heavy metal‐induced bladder cancer; however, its underlying molecular mechanism remains obscure. To comprehend the underlying mechanism, T24 and HT1376 bladder cancer cells were treated with eugenol alone, as well as in combinations with the individual heavy metals Cr and Cd, for 72 h. The concentrations of Cr and Cd were 8 μM each for T24 cells and 1 μM Cr and 2 μM Cd for HT1376 cells. Thereafter, cytotoxicity (MTT assay), apoptosis (AO/EtBr and Annexin V‐FITC/PI), ROS generation (DCFDA), and mitochondrial membrane potential (JC‐1) were assessed. Global DNA methylation and cell migration were evaluated through Flash Global DNA Methylation analysis epi Kit and transwell migration assay, respectively. Gene and protein expressions of Bax, Bcl‐2, caspase‐9, DNMTs, p53, p21, SOCS1, p‐Akt, and NF‐κB were assessed by qPCR and western blotting, respectively. Eugenol significantly reduced viability of T24 and HT1376 cells in a dose‐dependent manner and significantly inhibited Cr‐ and Cd‐induced cell proliferation. Additionally, the treatments resulted in ROS‐associated mitochondrial depolarization, increased Bax and caspase‐9 expressions, decreased Bcl‐2 level, reduced expression of DNMTs and global DNA methylation, restoration of p53, p21 and SOCS1, suppression of p‐Akt and NF‐κB, and marked inhibition of Cd‐ and Cr‐induced migration. Together, these findings show that eugenol may emerge as a promising candidate for modulation of DNMT activity, as well as a prophylactic candidate for bladder cancer prevention and/or treatment of heavy metal‐induced bladder carcinogenesis.
- 16 November 2026
- Published by Wiley in Environmental Toxicology
Eugenol Suppresses Heavy Metal‐Induced Proliferation of Urinary Bladder Cancer Cells Through Modulation of DNA Demethylation and Activation of the Intrinsic Apoptotic Pathway
Epigenetic dysregulation is triggered by environmental toxins, including heavy metals. The aberrant DNA methylation, catalyzed by DNA methyltransferases (DNMTs) in response to environmental toxins, plays a critical role in several diseases such as urinary bladder carcinogenesis. Dysregulated DNMT activity leads to genome‐wide alterations in the methylation pattern. Consequently, hypermethylation of tumor suppressor genes (TSGs) and global hypomethylation may result in genomic instability, oncogene activation, altered chromatin remodeling, and apoptosis. Although several DNMT inhibitors, including 5‐azacytidine and decitabine, are clinically approved, their instability and limited target specificity restrict their therapeutic applications. Therefore, researching novel compounds analogous to DNMT inhibitors with higher specificity may be therapeutically useful. In this context, eugenol has been found as a potential epigenetic modulator in relation to heavy metal‐induced bladder cancer; however, its underlying molecular mechanism remains obscure. To comprehend the underlying mechanism, T24 and HT1376 bladder cancer cells were treated with eugenol alone, as well as in combinations with the individual heavy metals Cr and Cd, for 72 h. The concentrations of Cr and Cd were 8 μM each for T24 cells and 1 μM Cr and 2 μM Cd for HT1376 cells. Thereafter, cytotoxicity (MTT assay), apoptosis (AO/EtBr and Annexin V‐FITC/PI), ROS generation (DCFDA), and mitochondrial membrane potential (JC‐1) were assessed. Global DNA methylation and cell migration were evaluated through Flash Global DNA Methylation analysis epi Kit and transwell migration assay, respectively. Gene and protein expressions of Bax, Bcl‐2, caspase‐9, DNMTs, p53, p21, SOCS1, p‐Akt, and NF‐κB were assessed by qPCR and western blotting, respectively. Eugenol significantly reduced viability of T24 and HT1376 cells in a dose‐dependent manner and significantly inhibited Cr‐ and Cd‐induced cell proliferation. Additionally, the treatments resulted in ROS‐associated mitochondrial depolarization, increased Bax and caspase‐9 expressions, decreased Bcl‐2 level, reduced expression of DNMTs and global DNA methylation, restoration of p53, p21 and SOCS1, suppression of p‐Akt and NF‐κB, and marked inhibition of Cd‐ and Cr‐induced migration. Together, these findings show that eugenol may emerge as a promising candidate for modulation of DNMT activity, as well as a prophylactic candidate for bladder cancer prevention and/or treatment of heavy metal‐induced bladder carcinogenesis.
- Open Access
- 20 August 2026
- Published by Wolters Kluwer Health in Indian Journal of Psychiatry
- Vol. 68 (8) , 709-717
Unmasking the invisible: Proteomic traces of depression in human serum - A pilot study
Background: Depression is a major cause of reduced productivity and increased morbidity. Aim: Given its complex and multifactorial pathophysiology, this study investigated serum proteomic profiles in individuals with depression and healthy controls to identify differentially expressed proteins and their functional significance. Methods: This is a cross-sectional observational study. Individuals with depression ( n = 6) were enlisted from the outpatient department of psychiatry at AIIMS Rishikesh, while age-matched healthy controls ( n = 6) were included for comparison. Peripheral whole blood samples were obtained from all participants under fasting conditions. Baseline characteristics were analyzed using Statistical Package for the Social Sciences, (IBM) 21. Continuous and categorical variables were expressed as mean ± SD and number (%), respectively. Proteomic data were analyzed and visualized using MetaboAnalyst 6.0, Cytoscape v3.10.3, Reactome Pathway, and SR plots. Result: In our main finding of the liquid chromatography–tandem mass spectrometry (LC-MS/MS) study of serum samples, a total of 242 proteins were identified, out of that 9 were upregulated and 11 were downregulated in the serum from the depression group and in the healthy control group. Receiver operating characteristic (ROC) analysis of significantly altered proteins showed strong discriminatory ability for fibrinogen, PSG9 , and AarF , with area under the curves (AUCs) of 0.944, 0.889, and 0.861, respectively. Conclusion: This study identifies a distinct molecular signature of depression, with PSG9, FGB, ADCK5, C8B , and SORCS1 emerging as key proteins. These markers reflect dysregulation of immune, vascular, mitochondrial, and signaling pathways, highlighting depression as a multisystem disorder, and offering potential targets for biomarker-based diagnosis and personalized therapeutic strategies.
- 20 August 2026
- Published by Wolters Kluwer Health in Indian Journal of Psychiatry
- Vol. 68 (8) , 709-717
Open AccessUnmasking the invisible: Proteomic traces of depression in human serum - A pilot study
Background: Depression is a major cause of reduced productivity and increased morbidity. Aim: Given its complex and multifactorial pathophysiology, this study investigated serum proteomic profiles in individuals with depression and healthy controls to identify differentially expressed proteins and their functional significance. Methods: This is a cross-sectional observational study. Individuals with depression ( n = 6) were enlisted from the outpatient department of psychiatry at AIIMS Rishikesh, while age-matched healthy controls ( n = 6) were included for comparison. Peripheral whole blood samples were obtained from all participants under fasting conditions. Baseline characteristics were analyzed using Statistical Package for the Social Sciences, (IBM) 21. Continuous and categorical variables were expressed as mean ± SD and number (%), respectively. Proteomic data were analyzed and visualized using MetaboAnalyst 6.0, Cytoscape v3.10.3, Reactome Pathway, and SR plots. Result: In our main finding of the liquid chromatography–tandem mass spectrometry (LC-MS/MS) study of serum samples, a total of 242 proteins were identified, out of that 9 were upregulated and 11 were downregulated in the serum from the depression group and in the healthy control group. Receiver operating characteristic (ROC) analysis of significantly altered proteins showed strong discriminatory ability for fibrinogen, PSG9 , and AarF , with area under the curves (AUCs) of 0.944, 0.889, and 0.861, respectively. Conclusion: This study identifies a distinct molecular signature of depression, with PSG9, FGB, ADCK5, C8B , and SORCS1 emerging as key proteins. These markers reflect dysregulation of immune, vascular, mitochondrial, and signaling pathways, highlighting depression as a multisystem disorder, and offering potential targets for biomarker-based diagnosis and personalized therapeutic strategies.
- 23 July 2026
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Untargeted LC-MS/MS profiling identifies ST18 as a novel serum marker for T2DM-associated depression
Depression is a prevalent but underdiagnosed comorbidity in type 2 diabetes mellitus (T2DM), intensifying disease burden and complicating metabolic management. Reliable biomarkers for early detection remain limited. This study aimed to identify serum protein signatures associated with depression in individuals with T2DM using an untargeted proteomic approach. Methods Serum samples from healthy controls, T2DM patients, and T2DM patients with comorbid depression (n = 6 per group) were analyzed using LC-MS/MS-based untargeted proteomics (total n = 18). Differential protein abundance was assessed using MetaboAnalyst 6.0. Protein-protein interaction networks and pathway enrichment analyses were conducted using the STRING database. Candidate markers were further validated by ELISA in an independent cohort of healthy controls (n = 30), T2DM (n = 30), and T2DM with depression (n = 30). Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves. Results LC-MS/MS identified 242 serum proteins, of which 12 were significantly dysregulated among the groups. Nine proteins showed unique alterations in the T2DM–depression group. STRING analysis highlighted ST18 as a central regulatory protein. ELISA validation confirmed significant elevation of LRG1, APOC2, and ST18 in T2DM with depression compared to controls and T2DM without depression. Among these, ST18 demonstrated the highest diagnostic accuracy, yielding the greatest area under the ROC curve. Conclusion Untargeted proteomic profiling revealed distinct serum protein alterations in T2DM patients with comorbid depression. ST18 emerged as a robust and specific biomarker, suggesting its potential involvement in the molecular interplay between metabolic dysregulation and depressive pathology. Larger, longitudinal studies are required to validate its predictive utility and clarify its role in T2DM-associated depression.
- 23 July 2026
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Untargeted LC-MS/MS profiling identifies ST18 as a novel serum marker for T2DM-associated depression
Depression is a prevalent but underdiagnosed comorbidity in type 2 diabetes mellitus (T2DM), intensifying disease burden and complicating metabolic management. Reliable biomarkers for early detection remain limited. This study aimed to identify serum protein signatures associated with depression in individuals with T2DM using an untargeted proteomic approach. Methods Serum samples from healthy controls, T2DM patients, and T2DM patients with comorbid depression (n = 6 per group) were analyzed using LC-MS/MS-based untargeted proteomics (total n = 18). Differential protein abundance was assessed using MetaboAnalyst 6.0. Protein-protein interaction networks and pathway enrichment analyses were conducted using the STRING database. Candidate markers were further validated by ELISA in an independent cohort of healthy controls (n = 30), T2DM (n = 30), and T2DM with depression (n = 30). Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves. Results LC-MS/MS identified 242 serum proteins, of which 12 were significantly dysregulated among the groups. Nine proteins showed unique alterations in the T2DM–depression group. STRING analysis highlighted ST18 as a central regulatory protein. ELISA validation confirmed significant elevation of LRG1, APOC2, and ST18 in T2DM with depression compared to controls and T2DM without depression. Among these, ST18 demonstrated the highest diagnostic accuracy, yielding the greatest area under the ROC curve. Conclusion Untargeted proteomic profiling revealed distinct serum protein alterations in T2DM patients with comorbid depression. ST18 emerged as a robust and specific biomarker, suggesting its potential involvement in the molecular interplay between metabolic dysregulation and depressive pathology. Larger, longitudinal studies are required to validate its predictive utility and clarify its role in T2DM-associated depression.
- Open Access
Cancer-Induced Cardiac Dysfunction: Mechanisms, Diagnostics, and Emerging Therapeutics in the Era of Onco-Cardiology
Cancer-induced cardiac dysfunction has become a major clinical challenge as advances in cancer therapies continue to extend patient survival. Once regarded as a secondary concern, cardiotoxicity is now recognized as a leading contributor to morbidity and mortality among cancer patients and survivors. Its pathophysiology is multifactorial, involving systemic inflammation (e.g., TNF-α, IL-6), oxidative stress driven by reactive oxygen species (ROS), neurohormonal imbalances (e.g., angiotensin II, endothelin-1), and metabolic disturbances. These mechanisms collectively promote cardiomyocyte apoptosis, atrophy, mitochondrial dysfunction, and impaired cardiac output. Cardiac complications may arise directly from cancer itself or as adverse effects of oncologic therapies such as anthracyclines, trastuzumab, and immune checkpoint inhibitors. These agents have been linked to heart failure (HF), systolic dysfunction, and cardiac atrophy, often progressing insidiously and underscoring the importance of early detection and careful monitoring. Current preventive and therapeutic strategies include pharmacological interventions such as ACE inhibitors, beta-blockers, statins, dexrazoxane, and endothelin receptor antagonists like atrasentan. Emerging compounds, particularly Withaferin A (WFA), have shown potential through their anti-inflammatory and cardiac protective properties. In addition, antioxidants and lifestyle modifications may provide supplementary cardioprotective benefits, while interventional cardiology procedures are increasingly considered in selected patients. Despite encouraging progress, standardized treatment protocols and robust long-term outcome data remain limited. Given the heterogeneity of cancer types and cardiovascular responses, a personalized and multidisciplinary approach is essential. Continued research and close collaboration between oncologists, cardiologists, and basic scientists will be the key to advancing care, reducing treatment-related morbidity, and ensuring that improvements in cancer survival are matched by preservation of cardiovascular health.
Open AccessCancer-Induced Cardiac Dysfunction: Mechanisms, Diagnostics, and Emerging Therapeutics in the Era of Onco-Cardiology
Cancer-induced cardiac dysfunction has become a major clinical challenge as advances in cancer therapies continue to extend patient survival. Once regarded as a secondary concern, cardiotoxicity is now recognized as a leading contributor to morbidity and mortality among cancer patients and survivors. Its pathophysiology is multifactorial, involving systemic inflammation (e.g., TNF-α, IL-6), oxidative stress driven by reactive oxygen species (ROS), neurohormonal imbalances (e.g., angiotensin II, endothelin-1), and metabolic disturbances. These mechanisms collectively promote cardiomyocyte apoptosis, atrophy, mitochondrial dysfunction, and impaired cardiac output. Cardiac complications may arise directly from cancer itself or as adverse effects of oncologic therapies such as anthracyclines, trastuzumab, and immune checkpoint inhibitors. These agents have been linked to heart failure (HF), systolic dysfunction, and cardiac atrophy, often progressing insidiously and underscoring the importance of early detection and careful monitoring. Current preventive and therapeutic strategies include pharmacological interventions such as ACE inhibitors, beta-blockers, statins, dexrazoxane, and endothelin receptor antagonists like atrasentan. Emerging compounds, particularly Withaferin A (WFA), have shown potential through their anti-inflammatory and cardiac protective properties. In addition, antioxidants and lifestyle modifications may provide supplementary cardioprotective benefits, while interventional cardiology procedures are increasingly considered in selected patients. Despite encouraging progress, standardized treatment protocols and robust long-term outcome data remain limited. Given the heterogeneity of cancer types and cardiovascular responses, a personalized and multidisciplinary approach is essential. Continued research and close collaboration between oncologists, cardiologists, and basic scientists will be the key to advancing care, reducing treatment-related morbidity, and ensuring that improvements in cancer survival are matched by preservation of cardiovascular health.
- Open Access
- 22 September 2025
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 17, 317-321
An insight into the association of sclerostin and disease activity in rheumatoid arthritis: A cross-sectional study
Objectives: Rheumatoid arthritis (RA) causes joint swelling and deformities, impacting quality of life. Wnt pathway dysregulation is linked to RA. Sclerostin (SOST), released from osteocytes, inhibits bone formation by interfering with Wnt signalling pathway and Dickkopf-1 (DKK-1) is a secreted protein which is also a inhibitor of the pathway. Receptor activator of nuclear factor kappa-beta (RANKL) induces osteoclast genesis and is opposed by osteoprotegerin (OPG). To investigate the role of SOST, DKK-1, OPG, and RANKL in the pathogenesis of RA cases in the Indian population, an observational study was conducted at All India Institute of Medical Sciences, Rishikesh. Materials and Methods: In this observational study, 38 RA cases and 38 controls were recruited. Serum levels of SOST, DKK-1, OPG, RANKL, and Beclin-1 were measured using enzyme-linked immunosorbent assay kits. Messenger RNA (mRNA) quantification was done by quantitative real-time polymerase chain reaction. An independent t -test/Mann–Whitney U-test was used to compare cases and controls. Spearman’s correlation coefficient was calculated to observe the association. Statistical analysis: Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 23. Mann Whitney U test/independent t-test was used for group comparison. Correlations were done using Spearman’s correlation test. Receiver operating characteristic (ROC) curve analysis used for predictive value of biomarkers. Results: The findings revealed that SOST expression was significantly higher in RA patients compared to controls and correlated with increased SOST mRNA expression. Moreover, there was a positive correlation of SOST with RANKL and disease activity score-28, and a negative correlation of SOST with beclin-1 and OPG. The ROC curve analysis revealed predictive value of SOST for detecting RA cases, with an optimal cutoff value of 24.70, sensitivity of 90.2%, and specificity of 64.4%. Conclusions: The study concludes that SOST might play an important role in RA severity and disease activity. Diagnosis accuracy might be improved by combining SOST assessment with additional markers (RANKL, OPG, DKK-1, or Beclin-1). Understanding the interplay of these markers could lead to novel therapeutic interventions for RA.
- 22 September 2025
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 17, 317-321
Open AccessAn insight into the association of sclerostin and disease activity in rheumatoid arthritis: A cross-sectional study
Objectives: Rheumatoid arthritis (RA) causes joint swelling and deformities, impacting quality of life. Wnt pathway dysregulation is linked to RA. Sclerostin (SOST), released from osteocytes, inhibits bone formation by interfering with Wnt signalling pathway and Dickkopf-1 (DKK-1) is a secreted protein which is also a inhibitor of the pathway. Receptor activator of nuclear factor kappa-beta (RANKL) induces osteoclast genesis and is opposed by osteoprotegerin (OPG). To investigate the role of SOST, DKK-1, OPG, and RANKL in the pathogenesis of RA cases in the Indian population, an observational study was conducted at All India Institute of Medical Sciences, Rishikesh. Materials and Methods: In this observational study, 38 RA cases and 38 controls were recruited. Serum levels of SOST, DKK-1, OPG, RANKL, and Beclin-1 were measured using enzyme-linked immunosorbent assay kits. Messenger RNA (mRNA) quantification was done by quantitative real-time polymerase chain reaction. An independent t -test/Mann–Whitney U-test was used to compare cases and controls. Spearman’s correlation coefficient was calculated to observe the association. Statistical analysis: Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) version 23. Mann Whitney U test/independent t-test was used for group comparison. Correlations were done using Spearman’s correlation test. Receiver operating characteristic (ROC) curve analysis used for predictive value of biomarkers. Results: The findings revealed that SOST expression was significantly higher in RA patients compared to controls and correlated with increased SOST mRNA expression. Moreover, there was a positive correlation of SOST with RANKL and disease activity score-28, and a negative correlation of SOST with beclin-1 and OPG. The ROC curve analysis revealed predictive value of SOST for detecting RA cases, with an optimal cutoff value of 24.70, sensitivity of 90.2%, and specificity of 64.4%. Conclusions: The study concludes that SOST might play an important role in RA severity and disease activity. Diagnosis accuracy might be improved by combining SOST assessment with additional markers (RANKL, OPG, DKK-1, or Beclin-1). Understanding the interplay of these markers could lead to novel therapeutic interventions for RA.
- Open Access
- 6 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e80186
Genetic Insights Into Early-Onset Type 2 Diabetes Mellitus: The Role of SOST and LRP5 Genotypic Variants in Young Indians
Background Type 2 diabetes mellitus (T2DM) presents a significant global health challenge, with increasing prevalence rates. The pathogenesis of early-onset T2DM is complex, with the Wnt signaling pathway playing a crucial role in islet cell development. Purpose This study was designed to explore the association of sclerostin (SOST) and low-density lipoprotein receptor-related protein-5 (LRP5) gene polymorphisms with early-onset T2DM in the young population of Uttarakhand, which is novel given that no studies have focused on this link within an Indian demographic. Methodology In this case-control study, T2DM patients between 20 and 40 years old who attended Medicine OPD were recruited as cases. After taking informed consent, 5 mL of blood was collected. Serum was used for lipid profile using the enzymatic method and sclerostin using the enzyme-linked immunosorbent assay (ELISA) method. DNA isolated from whole blood was subjected to polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for restriction digestion by NCoI and HinfI enzymes. Statistical analysis was done using IBM SPSS Statistics for Windows, Version 23 (Released 2015; IBM Corp., Armonk, New York). A comparison of genotypic variants was made using a chi-square test. Results In this study of 114 early-onset T2DM cases and 115 sex-matched controls, genotype distributions of the gene that codes for the protein sclerostin (SOST) rs865429 and LRP5 rs11228303 followed Hardy-Weinberg equilibrium. In cases, the SOST GG genotype showed a nonsignificant higher odds ratio (OR=2.035) for T2DM, and it was associated with higher low-density lipoprotein (LDL) levels (p=0.027), HbA1c, and triglycerides. The LRP5 CT genotype in cases was linked to significantly higher HbA1c (p=0.018) and elevated triglycerides and calcium, while the TT genotype showed the highest levels across multiple clinical parameters. The SOST GG genotype also suggested a possible link with bone metabolism due to elevated calcium, intact parathyroid hormone (iPTH), and sclerostin levels. These findings indicate potential interactions between SOST and LRP5 variants and metabolic markers in early-onset T2DM. Conclusion The trend of elevated biochemical parameters in GG and TT genotypes and higher odds ratio (OR=2.035) concludes that SOST and LRP5 variants may contribute to early-onset T2DM and related complications. These findings highlight the importance of genetic predisposition in T2DM, pointing to a need for personalized clinical approaches. Larger, multicenter studies are needed to confirm these preliminary results.
- 6 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e80186
Open AccessGenetic Insights Into Early-Onset Type 2 Diabetes Mellitus: The Role of SOST and LRP5 Genotypic Variants in Young Indians
Background Type 2 diabetes mellitus (T2DM) presents a significant global health challenge, with increasing prevalence rates. The pathogenesis of early-onset T2DM is complex, with the Wnt signaling pathway playing a crucial role in islet cell development. Purpose This study was designed to explore the association of sclerostin (SOST) and low-density lipoprotein receptor-related protein-5 (LRP5) gene polymorphisms with early-onset T2DM in the young population of Uttarakhand, which is novel given that no studies have focused on this link within an Indian demographic. Methodology In this case-control study, T2DM patients between 20 and 40 years old who attended Medicine OPD were recruited as cases. After taking informed consent, 5 mL of blood was collected. Serum was used for lipid profile using the enzymatic method and sclerostin using the enzyme-linked immunosorbent assay (ELISA) method. DNA isolated from whole blood was subjected to polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for restriction digestion by NCoI and HinfI enzymes. Statistical analysis was done using IBM SPSS Statistics for Windows, Version 23 (Released 2015; IBM Corp., Armonk, New York). A comparison of genotypic variants was made using a chi-square test. Results In this study of 114 early-onset T2DM cases and 115 sex-matched controls, genotype distributions of the gene that codes for the protein sclerostin (SOST) rs865429 and LRP5 rs11228303 followed Hardy-Weinberg equilibrium. In cases, the SOST GG genotype showed a nonsignificant higher odds ratio (OR=2.035) for T2DM, and it was associated with higher low-density lipoprotein (LDL) levels (p=0.027), HbA1c, and triglycerides. The LRP5 CT genotype in cases was linked to significantly higher HbA1c (p=0.018) and elevated triglycerides and calcium, while the TT genotype showed the highest levels across multiple clinical parameters. The SOST GG genotype also suggested a possible link with bone metabolism due to elevated calcium, intact parathyroid hormone (iPTH), and sclerostin levels. These findings indicate potential interactions between SOST and LRP5 variants and metabolic markers in early-onset T2DM. Conclusion The trend of elevated biochemical parameters in GG and TT genotypes and higher odds ratio (OR=2.035) concludes that SOST and LRP5 variants may contribute to early-onset T2DM and related complications. These findings highlight the importance of genetic predisposition in T2DM, pointing to a need for personalized clinical approaches. Larger, multicenter studies are needed to confirm these preliminary results.
- Open Access
- 28 July 2023
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 16, 153-159
Predictive value of adiposity index in identifying depression in individuals with type 2 diabetes mellitus in Indian population
Objectives: Type 2 diabetes mellitus (T2DM) patients are four times more prone to develop depression. Common subjective tool to evaluate depression is Patient Health Questionnaire-9 (PHQ-9). Depression in T2DM remains unaddressed because of lack of objective tools resulting in poor treatment compliance. Both obesity and metabolic disturbances could influence mental health status. Therefore, this study was designed to determine the better adiposity index to predict depression in T2DM. Materials and Methods: In this clinic-based cross-sectional study, 400 individuals (260 = T2DM and 140 = healthy) were recruited. Based on PHQ-9, T2DM patients were divided into T2DM + Dep (PHQ-9 ≤ 10) and T2DM-Dep (PHQ-9 < 10). The relationship between the PHQ-9 score and adiposity indices was examined by Pearson’s/Spearman’s correlation. The receiver-operating characteristic curve analysis was used to identify the cutoff value. Statistical Analysis: Statistical analysis was performed using SPSS 22.0 version (IBM Corp., Armonk, New York, United States). Results: Female diabetic patients showed significant correlation only in lipid accumulation product index (LAPI) and visceral adiposity index (VAI) (r = 0.206 and r = 0.0.237, respectively), while male diabetic patients did not show any significant association. Interestingly, T2DM + Dep group showed significant association between LAPI (r = 0.248) with PHQ-9 score, while T2DM-Dep group did not show significant association. VAI had maximum area under the curve in T2DM patients (0.619, p = 0.002) as well as in female diabetic patients (0.684, p = 0.002). The cutoff value for identifying depression among diabetic individuals was 5.60, with 70.3% sensitivity and 48.2% specificity, while in diabetic females, it was 6.612, with 70% sensitivity and 61.4% specificity. Conclusions: VAI might be the best adiposity index to predict depression among diabetic individuals.
- 28 July 2023
- Published by Scientific Scholar in Journal of Laboratory Physicians
- Vol. 16, 153-159
Open AccessPredictive value of adiposity index in identifying depression in individuals with type 2 diabetes mellitus in Indian population
Objectives: Type 2 diabetes mellitus (T2DM) patients are four times more prone to develop depression. Common subjective tool to evaluate depression is Patient Health Questionnaire-9 (PHQ-9). Depression in T2DM remains unaddressed because of lack of objective tools resulting in poor treatment compliance. Both obesity and metabolic disturbances could influence mental health status. Therefore, this study was designed to determine the better adiposity index to predict depression in T2DM. Materials and Methods: In this clinic-based cross-sectional study, 400 individuals (260 = T2DM and 140 = healthy) were recruited. Based on PHQ-9, T2DM patients were divided into T2DM + Dep (PHQ-9 ≤ 10) and T2DM-Dep (PHQ-9 < 10). The relationship between the PHQ-9 score and adiposity indices was examined by Pearson’s/Spearman’s correlation. The receiver-operating characteristic curve analysis was used to identify the cutoff value. Statistical Analysis: Statistical analysis was performed using SPSS 22.0 version (IBM Corp., Armonk, New York, United States). Results: Female diabetic patients showed significant correlation only in lipid accumulation product index (LAPI) and visceral adiposity index (VAI) (r = 0.206 and r = 0.0.237, respectively), while male diabetic patients did not show any significant association. Interestingly, T2DM + Dep group showed significant association between LAPI (r = 0.248) with PHQ-9 score, while T2DM-Dep group did not show significant association. VAI had maximum area under the curve in T2DM patients (0.619, p = 0.002) as well as in female diabetic patients (0.684, p = 0.002). The cutoff value for identifying depression among diabetic individuals was 5.60, with 70.3% sensitivity and 48.2% specificity, while in diabetic females, it was 6.612, with 70% sensitivity and 61.4% specificity. Conclusions: VAI might be the best adiposity index to predict depression among diabetic individuals.
- Open Access
Genetic Variations in IL-1β, TNF-α, and TGF-β Associated with the Severity of Chronic Cervical Spondylitis in Patients
Chronic cervical spondylitis (CCS), a degenerative disorder of the spine, is known for causing disability among old and young people. Single-nucleotide polymorphisms (SNPs) in various cytokine genes have demonstrated an impactful association with several inflammatory disorders. In the present study, we have investigated the SNPs and allelic distribution of the three most prevalent cytokines genes, IL-1β (-511C/T), TNF-α (-308G/A), and TGF-β (-509C/T), along with serum levels of these cytokines in 252 subjects. SNPs were analyzed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and digested fragments were separated and visualized using agarose gel electrophoresis and Native Polyacrylamide gel electrophoresis (PAGE). The serum cytokine levels were analyzed with a flow cytometer using a customized multiplex bead-based assay. It was observed that these SNPs did not reflect the susceptibility to CCS but were associated with susceptibility to CCS. We found a significant association between the C/C and G/G genotypes and the C and G alleles of IL-1β and TNF-α, respectively, suggesting a lower risk of CCS. The frequency distribution of risk alleles (-511T) and (-308A) were simultaneously higher in CCS compared to the control, reflecting the susceptibility to CCS. TGF-β showed a significant association with disease susceptibility, along with a significant correlation between age and the chronicity of CCS. The serum cytokine levels were significantly different in CCS and controls.
Open AccessGenetic Variations in IL-1β, TNF-α, and TGF-β Associated with the Severity of Chronic Cervical Spondylitis in Patients
Chronic cervical spondylitis (CCS), a degenerative disorder of the spine, is known for causing disability among old and young people. Single-nucleotide polymorphisms (SNPs) in various cytokine genes have demonstrated an impactful association with several inflammatory disorders. In the present study, we have investigated the SNPs and allelic distribution of the three most prevalent cytokines genes, IL-1β (-511C/T), TNF-α (-308G/A), and TGF-β (-509C/T), along with serum levels of these cytokines in 252 subjects. SNPs were analyzed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and digested fragments were separated and visualized using agarose gel electrophoresis and Native Polyacrylamide gel electrophoresis (PAGE). The serum cytokine levels were analyzed with a flow cytometer using a customized multiplex bead-based assay. It was observed that these SNPs did not reflect the susceptibility to CCS but were associated with susceptibility to CCS. We found a significant association between the C/C and G/G genotypes and the C and G alleles of IL-1β and TNF-α, respectively, suggesting a lower risk of CCS. The frequency distribution of risk alleles (-511T) and (-308A) were simultaneously higher in CCS compared to the control, reflecting the susceptibility to CCS. TGF-β showed a significant association with disease susceptibility, along with a significant correlation between age and the chronicity of CCS. The serum cytokine levels were significantly different in CCS and controls.
- Open Access
Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study
COVID-19 has caused devastating effects worldwide ever since its origin in December 2019. IL-6 is one of the chief markers used in the management of COVID-19. We conducted a longitudinal study to investigate the role of IL-6 in diagnosis, treatment, and prognosis of COVID-19-related cytokine storm. Patients with COVID-19 who were admitted at AIIMS Rishikesh from March to December 2020 were included in the study. Patients with no baseline IL-6 value at admission and for whom clinical data were not available were excluded. Clinical and laboratory data of these patients were collected from the e-hospital portal and entered in an excel sheet. Correlation was seen with other inflammatory markers and outcomes were assessed using MS Excel 2010 and SPSS software. A total of 131 patients were included in the study. Of these, 74.8% were males, with mean age 55.03 ± 13.57 years, and mean duration from symptom onset being 6.69 ± 6.3 days. A total of 82.4% had WHO severe category COVID-19, with 46.56% having severe hypoxia at presentation and 61.8% of them having some comorbidity. Spearman rank correlation coefficient of IL-6 with D-dimer was 0.203, with LDH was −0.005, with ferritin was 0.3, and with uric acid was 0.123. A total of 11 patients received Tocilizumab at a mean duration from symptom onset of 18.09 days, and 100% mortality was observed. Deaths were reported more in the group with IL-6 ≥ 40 pg/mL (57.1% vs. 40.2%, p = 0.06). ICU admissions and ventilator requirement were higher in the IL-6 ≥ 40 pg/mL group (95.9% vs. 91.4%, p = 0.32 and 55.1% vs. 37.8%, p = 0.05). The study showed that IL-6 can be used as a possible “thrombotic cytokine marker”. Higher values of IL-6 (≥40 pg/mL) are associated with more deaths, ICU admissions, and ventilator requirement.
Open AccessUtility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study
COVID-19 has caused devastating effects worldwide ever since its origin in December 2019. IL-6 is one of the chief markers used in the management of COVID-19. We conducted a longitudinal study to investigate the role of IL-6 in diagnosis, treatment, and prognosis of COVID-19-related cytokine storm. Patients with COVID-19 who were admitted at AIIMS Rishikesh from March to December 2020 were included in the study. Patients with no baseline IL-6 value at admission and for whom clinical data were not available were excluded. Clinical and laboratory data of these patients were collected from the e-hospital portal and entered in an excel sheet. Correlation was seen with other inflammatory markers and outcomes were assessed using MS Excel 2010 and SPSS software. A total of 131 patients were included in the study. Of these, 74.8% were males, with mean age 55.03 ± 13.57 years, and mean duration from symptom onset being 6.69 ± 6.3 days. A total of 82.4% had WHO severe category COVID-19, with 46.56% having severe hypoxia at presentation and 61.8% of them having some comorbidity. Spearman rank correlation coefficient of IL-6 with D-dimer was 0.203, with LDH was −0.005, with ferritin was 0.3, and with uric acid was 0.123. A total of 11 patients received Tocilizumab at a mean duration from symptom onset of 18.09 days, and 100% mortality was observed. Deaths were reported more in the group with IL-6 ≥ 40 pg/mL (57.1% vs. 40.2%, p = 0.06). ICU admissions and ventilator requirement were higher in the IL-6 ≥ 40 pg/mL group (95.9% vs. 91.4%, p = 0.32 and 55.1% vs. 37.8%, p = 0.05). The study showed that IL-6 can be used as a possible “thrombotic cytokine marker”. Higher values of IL-6 (≥40 pg/mL) are associated with more deaths, ICU admissions, and ventilator requirement.